Metabolic Effects of Four-week Lactate-ketone Ester Supplementation

Last updated: April 1, 2025
Sponsor: University of Aarhus
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Diabetes Prevention

Obesity

Treatment

LaKe Ester

Placebo

Clinical Study ID

NCT05917873
98128
  • Ages 30-60
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Recent research reveals intriguing results concerning the role of exogenous lactate and the ketone body 3-hydroxybutyrate (3-OHB) as therapeutic tools to combat obesity and related conditions. Thus, oral administration of lactate and 3-OHB have separately been shown to suppress appetite sensations and slow gastric emptying while administered orally. Both seem to inhibit lipolysis while oral 3-OHB administration have shown direct insulin sensitizing effects. Furthermore, both substrates can be used as fuel for the heart.

The goal of this placebo-controlled randomized crossover design is to test exogenous lactate and the ketone body 3-hydroxybutyrate (3-OHB) in healthy, non-diabetic, obese adults.

The main questions it aims to answer are if chronic administration of LaKe ester affect or improve the following endpoints:

  • Insulin sensitivity

  • Appetite sensations

  • Gastric emptying

  • Lipolysis

  • Cardiac output

  • Left Ventricular Ejection Fraction

  • Global Longitudinal Strain and other echocardiographic measures listed below

Participants will ingest a combined lactate and ketone body ester (LaKe ester) or placebo twice a day for 28 days before experimental days.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age between 30-60 years

  • BMI range 30-40

  • Glycated haemoglobin (HbA1c) < 48 mmol/mol

  • Otherwise 'healthy'

  • Written and oral consent

Exclusion

Exclusion Criteria:

  • Medication that affect energy or glucose metabolism, eg metformin, insulin orGlucagon-like peptide-1 receptor (GLP-1) agonists

  • Specific diets (eg practicing ketogenic diets)

  • Cardiac arrhythmias (eg atrial fibrillation)

  • Ongoing acute/chronic serious diseases (eg, anemia, chronic kidney or liver disease)

  • Inability to understand Danish or English

Study Design

Total Participants: 10
Treatment Group(s): 2
Primary Treatment: LaKe Ester
Phase:
Study Start date:
September 07, 2023
Estimated Completion Date:
December 31, 2025

Connect with a study center

  • Steno Diabetes Center Aarhus

    Aarhus, 8200
    Denmark

    Site Not Available

+−

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.